# ACIP Dengue Vaccine Workgroup

Wilbur Chen, MD, MSc
Katherine A. Poehling, MD, MPH
ACIP Members and Workgroup Co-Chairs
Advisory Committee on Immunization Practices
ACIP Meeting May 5th, 2021

### **ACIP Dengue Vaccines Workgroup**

**ACIP Members** 

Kathy Poehling (Co-chair)

Wilbur Chen (Co-Chair)

Beth Bell

Veronica McNally

CDC Lead

Gabriela Paz-Bailey

**Ex Officio Members** 

Kaitlyn Morabito (NIH)

Ralph LeBlanc (FDA)

Kirk Prutzman (FDA)

Srihari Seshadri (DOD)

<u>Liaison Representatives</u>

Elizabeth Barnett (AAP)

Rob Schechter (AIM)

**Consultants** 

**Edwin Asturias** 

**Robert Atmar** 

Alan Barrett

Anna Durbin

Ines Esquilin

Tony Marfin

Hal Margolis

Kristen Pierce

**Anita Shet** 

Steve Waterman

**CDC Contributors** 

Laura Adams

Mimi Eckert

Rachel Eidex

Susan Hills

Terri Hyde

Mike McNeil

Jorge Munoz

Erin Staples

Cindy Weinbaum

Rita Helfand

# Dengvaxia timeline

2015
Phase 3 results
>risk hosp. 2-5y

2016
WHO/SAGE
recommendatio
n 9-45y in high
seroprevalence
areas

2017
Case-cohort
study shows
increase risk of
severe dengue
among
serostatus

2018
WHO revised recommendation to screen + vaccinate ACIP dengue vaccine workgroup

2019
FDA licences
dengue vaccine

2021
ACIP vote on recommendation

# Dengue vaccine workgroup discussions

2019

2017

Dengue epi and vaccine development

Phase 3 results
Safety & pharmacovigilance
GRADE
Cost effectiveness
Dengue Diagnostics
Dengue vaccine in Philippines
VRBPAC review
FDA approval

2021

Dengue IgG test evaluation
Evidence to recommendations
framework (EtR)
Draft recommendations to
ACIP



WG on hold
Flavivirus WG split
Dengue Vaccine
Workgroup is
formed

#### 2020

Vaccine acceptability
WHO global position
Feasibility
Health Equity

# Dengue Vaccine Workgroup discussions Feb-May 2021

- Performance recommendations for a pre-vaccination screening test
- Evidence to recommendations framework
- Key messages for providers and families

# ACIP February 24-25, 2021 Importance of a specific test for pre-vaccination screening

- CYD-TCV vaccine requires pre-vaccination screening
- Pre-vaccination dengue screening needs to be
  - specific to minimize vaccination of seronegative children
  - sensitive to maximize identification of children who can benefit
- Test performance characteristics to be included with ACIP recommendations
- CDC evaluation identified one ELISA tests and two rapid tests meeting recommended criteria with high specificity and sensitivity

### **ACIP Schedule 2021**

- ACIP May 2021 Meeting
  - EtR and draft WG recommendations (NO VOTE)
- ACIP June 2021 Meeting
  - ACIP vote CYD TDV recommendations

## Presentation today

Dengue vaccine

Evidence to recommendations framework

Gabriela Paz Bailey, MD, PhD, MSc

Dengue Branch, Division of Vector-Borne Diseases, CDC